Combined anticancer therapy with imidazoacridinone analogue C‐1305 and paclitaxel in human lung and colon cancer xenografts—Modulation of tumour angiogenesis

Triazoloacridone C-1305 impairs XBP1 splicing by acting as a potential IRE1α endoribonuclease inhibitor

(2021) Sylwia Bartoszewska et al.   CELLULAR & MOLECULAR BIOLOGY LETTERS

Utilizing Genome-Wide mRNA Profiling to Identify the Cytotoxic Chemotherapeutic Mechanism of Triazoloacridone C-1305 as Direct Microtubule Stabilization

(2020) Jarosław Króliczewski et al.   Cancers

Electrochemical and in silico approaches for liver metabolic oxidation of antitumor-active triazoloacridinone C-1305

(2020) Agnieszka Potęga et al.   Journal of Pharmaceutical Analysis

Enhanced Activity of P4503A4 and UGT1A10 Induced by Acridinone Derivatives C-1305 and C-1311 in MCF-7 and HCT116 Cancer Cells: Consequences for the Drugs’ Cytotoxicity, Metabolism and Cellular Response

(2020) Monika Pawłowska et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A strong preference for the TA/TA dinucleotide step discovered for an acridine-based, potent antitumor dsDNA intercalator, C-1305: NMR-driven structural and sequence-specificity studies

(2020) Tomasz Laskowski et al.   Scientific Reports

Modulation of UDP-glucuronidation by acridinone antitumor agents C-1305 and C-1311 in HepG2 and HT29 cell lines, despite slight impact in noncellular systems

(2018) Anna Bejrowska et al.   Pharmacological Reports

Transforming growth factor-β: A therapeutic target for cancer

(2017) Sulsal Haque et al.   Human Vaccines & Immunotherapeutics

Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer

(2017) R. L. Capizzi et al.   JOURNAL OF CLINICAL ONCOLOGY

C-1311, a novel inhibitor of FLT3 and topoisomerase II: A phase 1 trial of a once every three week schedule in patients with advanced solid tumors

(2017) A. L. Thomas et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiangiogenic cancer treatment: The great discovery and greater complexity (Review)

(2016) Ewa Maj et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Mechanism-based inactivation of human cytochrome P450 1A2 and 3A4 isoenzymes by anti-tumor triazoloacridinone C-1305

(2016) Agnieszka Potęga et al.   XENOBIOTICA

The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells

(2015) Ewa Augustin et al.   ACTA PHARMACOLOGICA SINICA

Tubulin Beta3 Serves as a Target of HDAC3 and Mediates Resistance to Microtubule-Targeting Drugs

(2015) Youngmi Kim et al.   MOLECULES AND CELLS

Use of Yeast Chemigenomics and COXEN Informatics in Preclinical Evaluation of Anticancer Agents

(2015) Steven C. Smith et al.   NEOPLASIA

CYP3A4-dependent cellular response does not relate to CYP3A4-catalysed metabolites of C-1748 and C-1305 acridine antitumor agents in HepG2 cells

(2014) Ewa Augustin et al.   CELL BIOLOGY INTERNATIONAL

Pregnane X receptor dependent up-regulation of CYP2C9 and CYP3A4 in tumor cells by antitumor acridine agents, C-1748 and C-1305, selectively diminished under hypoxia

(2013) Magdalena Niemira et al.   BIOCHEMICAL PHARMACOLOGY

Modulation of CYP3A4 activity and induction of apoptosis, necrosis and senescence by the anti-tumour imidazoacridinone C-1311 in human hepatoma cells

(2013) Ewa Augustin et al.   CELL BIOLOGY INTERNATIONAL

Randomized Phase II Study of Ixabepilone or Paclitaxel Plus Carboplatin in Patients With Non–Small-Cell Lung Cancer Prospectively Stratified by Beta-3 Tubulin Status

(2013) Martin J. Edelman et al.   JOURNAL OF CLINICAL ONCOLOGY

A Dominant-Negative FGF1 Mutant (the R50E Mutant) Suppresses Tumorigenesis and Angiogenesis

(2013) Seiji Mori et al.   PLoS One

PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells

(2012) Józefa Węsierska-Gądek et al.   BIOCHEMICAL PHARMACOLOGY

The Imidazoacridinone Antitumor Drug, C-1311, Is Metabolized by Flavin Monooxygenases but Not by Cytochrome P450s

(2011) A. Potega et al.   DRUG METABOLISM AND DISPOSITION

Flavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of anti-tumour triazoloacridinone, C-1305, in liver microsomes and HepG2 cells

(2011) Barbara Fedejko-Kap et al.   XENOBIOTICA

Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints

(2010) Michal Sabisz et al.   BIOCHEMICAL PHARMACOLOGY

Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours

(2009) N. Isambert et al.   EUROPEAN JOURNAL OF CANCER